Document is current
Any future updates will be listed below
-
Authors
Andréasson, Mattias https://orcid.org/0000-0003-3472-3947
Lagali, Neil https://orcid.org/0000-0003-1079-4361
Badian, Reza A. https://orcid.org/0000-0003-1773-3780
Utheim, Tor Paaske
Scarpa, Fabio
Colonna, Alessia
Allgeier, Stephan https://orcid.org/0000-0002-1218-448X
Bartschat, Andreas
Köhler, Bernd https://orcid.org/0000-0002-8124-2938
Mikut, Ralf
Reichert, Klaus-Martin
Solders, Göran
Samuelsson, Kristin
Zetterberg, Henrik
Blennow, Kaj
Svenningsson, Per https://orcid.org/0000-0001-6727-3802
- License Information
-
More Information
Article History
Received: 28 July 2020
Accepted: 12 November 2020
First Online: 5 January 2021
Competing interests
: M.A. received funding from Hofgren’s fond, NEURO Sweden, for the present study. S.A., A.B., B.K., R.M. were funded by the Deutsche Forschungsgemeinschaft for the development of analysis methods and tools used in this study. H.Z. has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, and CogRx, has given lectures in symposia sponsored by Fujiebro, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. N.L., R.A.B., T.P.U., F.S., A.C., KM.R., G.S., K.S., K.B. report no competing interests. P.S. reports research grants from Parkinsonfonden and Wallenberg Clinical Scholarship; an honorarium from AbbVie.
